Studying tumour DNA in blood and tissue samples from people with advanced thyroid cancer
Collects blood and tissue samples from adults with advanced thyroid cancer to study tumour DNA.
Plain-language title generated from the registry record
Registry title: Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer
Key facts
- Where
- London, United KingdomSee the site
Where in United Kingdom
- The Royal Marsden NHS Foundation TrustLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal Marsden NHS Foundation Trust
- Trial code
- NCT05837260
- Record updated
- 9 August 2024
- Original description
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctDNA at baseline of eligible patients.Read full original descriptionShow less
A Multicentre Prospective Study Investigating the Utility of ctDNA as a Biomarker of Disease Burden, Genetic Heterogeneity and Tumour Evolution in Advanced Thyroid Cancer
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctDNA at baseline of eligible patients.
Inclusion: Age 18 years or older. (all cohorts); Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1); Patients with newly diagnosed resectable locally advanced medullary thyroid cancer Or Patients with newly diagnosed metastatic medullary thyroid cancer for surveillance Or Patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2); Patients with RR-DTC starting systemic therapy Or Patients with RR-DTC on systemic therapy Or Patients with MTC starting systemic therapy Or Patients with MTC on systemic therapy (cohort 3); Patients with newly diagnosed anaplastic thyroid cancer (cohort 4); Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts); Patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts); Ability to give informed consent for biological sample collection. (all cohorts).
Exclusion: Previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete sample collection; Any invasive malignancy within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ); Pregnancy.